Most Viewed Articles of 2023

2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year. Top 20 Radiopharma Companies Based on Market Cap Shots: Integrating scintigraphy with…

BySaurabh ChaubeyJanuary 2, 2024

INSIGHTS+

Insights+: The US FDA New Drug Approvals in November 2023

Shots: The US FDA approved 5 NDAs & 4 BLAs in November 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 109 novel products in 2023 In November 2023, the major highlights drugs were Wezlana (ustekinumab) approved for Multiple Inflammatory Diseases, and Cosentyx (secukinumab) for the Treatment…

BySenior EditorDecember 20, 2023

INSIGHTS+

Insights+: The US FDA New Drug Approvals in October 2023

Shots: The US FDA approved 5 NDAs & 9 BLAs in October 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 98 novel products in 2023 In October 2023, the major highlights drugs were Velsipity (Etrasimod) approved for Ulcerative Colitis, and Bimzelx (bimekizumab) for the Treatment of Adults…

BySenior EditorNovember 15, 2023

TOP 20

Top 20 Companies Spending on R&D in 2022

Shots:R&D (Research and Development) in the biopharma industry lays the foundation stone of innovative drugs. A robust R&D bolstered with new-age technological advances assures long-term sustainability in the future marketWith a global expenditure of $238B in 2022, the figures are anticipated to reach $285B by 2028. In 2022, AbbVie ranked the top among…

ByPrince GiriAugust 22, 2023

TOP 20

Top 20 Companies Spending on R&D in 2022

Shots:R&D (Research and Development) in the biopharma industry lays the foundation stone of innovative drugs. A robust R&D bolstered with new-age technological advances assures long-term sustainability in the future marketWith a global expenditure of $238B in 2022, the figures are anticipated to reach $285B by 2028. In 2022, AbbVie ranked the top among…

ByPrince GiriAugust 22, 2023

INSIGHTS+

Insights+ Key Biosimilars Events of July 2023

Shots:Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of July, Samsung Bioepis reported P-III equivalence study…

BySenior EditorAugust 4, 2023

INSIGHTS+

Top Performing Drug – Enbrel (June Edition)

Shots:In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Enbrel as the top-performing drug of the monthEnbrel is a biologic drug classified as a TNF inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune diseasesPharmaShots…

BySenior EditorJune 28, 2023

INSIGHTS+

Insights+ Key Biosimilars Events of May 2023

Shots:Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyBiosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patientsDuring the month of May, Celltrion’s Yuflyma (biosimilar, adalimumab) received the…

BySenior EditorJune 7, 2023

THOUGHTSPOT

Intelligent Automation in Pharmaceutical Industry (AI & ML)

Shots:Driven by the influx of life-changing innovations and technological advances, the pharmaceutical industry is forging ahead at a momentous pace. With the impelling Pharma 4.0, automation has now been embedded in various aspects of current business practices Delving deeply into the importance of automation, primarily focusing on AI & ML, PharmaShots unveils its eight-step…

BySaurabh ChaubeyJune 6, 2023

TOP 20

Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

Shots:Standing tall and gradually paving its way through extensive research, Cell & Gene Therapy is a beacon of hope when treating rare and inherited diseases. Cell and gene therapy aims to prevent, treat, and potentially reduce the effects of the underlying cause of genetic diseases.Propelled by constant innovatory winds, the cell and gene…

BySenior EditorMay 23, 2023

Most Viewed Articles of 2023

Insights+: The US FDA New Drug Approvals in November 2023

Insights+: The US FDA New Drug Approvals in October 2023

Top 20 Companies Spending on R&D in 2022

Top 20 Companies Spending on R&D in 2022

Insights+ Key Biosimilars Events of July 2023

Top Performing Drug – Enbrel (June Edition)

Insights+ Key Biosimilars Events of May 2023

Intelligent Automation in Pharmaceutical Industry (AI & ML)

Top 20 Cell and Gene Therapy Companies Based on 2022 Total Revenue

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter